Aquestive therapeutics announces ceo transition

Warren, n.j., may 17, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that keith kendall, president and chief executive officer and member of the board of directors of the company, is leaving the company. the board of directors has appointed daniel barber, the current chief operating officer and long-tenured executive of the company, to succeed mr. kendall as the president and chief executive officer of aquestive and member of its board of directors, effective immediately. the company and mr. kendall entered into a consulting agreement effective upon his departure. under the terms of the consulting agreement, mr. kendall will assist in the transition of the role of ceo and the execution of the company's business strategy and operations until the end of the year.
AQST Ratings Summary
AQST Quant Ranking